Aberrant methylation of the negative regulators RASSF1A, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia

British Journal of Haematology

Volumn 129, Issue 1, 2005, Pages 60-65

  Johan, M F ^a   Bowen, D T ^b   Frew, M E ^b   Goodeve, A C ^a   Reilly, J T ^a  

^a Academic Unit of Haematology   (United Kingdom)

^b NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

Acute myeloid leukaemia; Myelodysplastic syndromes; RASSF1A; SHP 1; SOCS 1

Indexed keywords

ONCOPROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RAS PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CONTROLLED STUDY; DNA METHYLATION; EXON; GENE CONTROL; GENE LOCATION; GENE MUTATION; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION;

ACUTE DISEASE; DNA METHYLATION; DNA, NEOPLASM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID; MYELODYSPLASTIC SYNDROMES; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PROTEIN-TYROSINE-PHOSPHATASE; REPRESSOR PROTEINS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; SHP1 PROTEIN TYROSINE PHOSPHATASE; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 17144366936     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05412.x     Document Type: Article

References (35)

1. Abu-Duhier, P.M., Goodeve, A.C., Wilson, G.A., Care, R.S., Peake, I.R. & Rally, J.T. (2001) Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. British Journal of Haematology, 113, 983-988.
2. Agathanggelou, A., Honorio, S., Macartney, D.P., Martinez, A., Dallol, A., Rader, J., Fullwood, P., Chauhan, A., Walker, R., Shaw, J.A., Hosoe, S., Lerman, M.I., Minna, J.D., Maher, E.R. & Latif, F. (2001) Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breasts and ovarian tumors. Oncogene, 20, 1509-1518.
3. Bignon, J.S. & Siminovitch, K.A. (1994) Identification of PTP1C mutation as the genetic defect in motheaten and viable motheaten: a step toward defining the roles of protein tyrosine phosphatases in the regulation of hematopoietic cell differentiation and function. Clinical Immunology and Immunopathology, 73, 168-179.
4. Care, R.S., Valk, P.J., Goodeve, A.C., Abu-Duhier, P.M., Geertsma-Kleinekoort, W.M., Wilson, G.A., Gari, M.A., Peake, I.R., Lowenberg, B. & Reilly, J.T. (2003) Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. British Journal of Haematology, 121, 775-777.
5. Chen, C.Y., Tsay, W., Tang, J.L., Shen, H.L., Lin, S.W., Huang, S.Y., Yao, M., Chen, Y.C., Shen, M.C., Wang, CH. & Tien, H.F. (2003) SOCS1 methylation in patients with newly diagnosed acute myeloid leukemias. Genes, Chromosomes and Cancer, 37, 300-305.
6. Chim, C-S., Fung, T-K., Cheung, W-C., Liang, R. & Kwong, Y-L. (2004a) SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood, 103, 4630-4635.
7. Chim, C.S., Wong, A.S.Y. & Kwong, Y.L. (2004b) Epigenetic dysregulation of the Jak/STAT pathway by frequent aberrant methylation of SHP1 but not SOCS1 in acute leukaemias. Annals of Hematology, 83, 527-532.
8. Dammann, R., Li, C., Yoon, J.H., Chin, P.L., Bates, S. & Pfeifer, G.P. (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumor suppressor locus 3p21.3, Nature Genetics, 25, 315-319.
9. Dammann, R., Schagdarsurengin, U., Liu, L., Otto, N., Gimm, O., Dralle, H., Boehm, B.O., Pfeifer, G.P. & Hoang-Vu, C. (2003) Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene, 22, 3806-3812.
10. van Engleland, M., Roemen, G.M., Brink, M., Pachen, M.M., Weijenberg, M.P., de Bruine, A.P., Arends, J.W., van den Brandt, P.A., de Goeij, A.F. & Herman, J.G. (2002) K-ras mutations and RASSF1A promotor methylation in colorectal cancer. Oncogene, 21, 3792-3795.
11. Galm, O., Yoshikawa, H., Esteller, M., Osieka, R. & Herman, J.G. (2003) SOCS-1, a negative regulator of cytokine signalling, is frequently silenced by methylation in multiple myeloma. Blood, 101, 2784-2788.
12. Gari, M., Goodeve, A., Wilson, G., Winship, P., Langabeer, S., Linch, D., Vandenberghe, E., Peake, I. & Reilly, J. (1999) c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. British Journal of Haematology, 105, 894-900.
13. Harada, K., Toyooka, S., Maitra, A., Maruyama, R., Toyooka, K.O., Timmons, C.F., Tomlinson, G.E., Mastrangelo, D., Hay, R.J., Minna, J.D. & Gazdar, A.F. (2002) Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene, 21, 4345-4349.
14. Heinrich, P.C., Behrmann, I., Haan, S., Hermanns, H.M., Müller-Newen, G. & Schaper, F. (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochemistry Journal, 374, 1-20.
15. Herman, J.G., Graff, J.R., Myohanen, S., Nelkin, B.D. & Baylin, S.B. (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proceedings of the National Academy of Sciences of the United States of America, 93, 9821-9826.
16. Klingmuller, U., Lorenz, U., Cantley, L.C., Neel, B.C. & Lodish, H.F. (1995) Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell, 80, 729-738.
17. Kohl, T.M., Schnittger, S., Ellwart, J.W., Hiddemann, W. & Spiekermann, K. (2004) Kit exon 8 mutations associated with core binding factor (CBF) - acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood doi: 10.1182/ blood-2004-06-2068 (published online 23 December 2004).
18. Liu, T.C., Lin, S.F., Chang, J.G., Yang, M.Y., Hung, S.Y. & Chang, C.S. (2003) Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. British Journal of Haematology, 123, 654-661.
19. Lo, K., Kwong, J., Hui, A.B., Chan, S.Y., to, K., Chan, A.S., Chow, L.S., Teo, P.M.L, Johnson, P.J. & Huang, D.P. (2001) High frequency of promoter hypermethylation of RASS1A in nasopharyngeal carcinoma. Cancer Research, 61, 3877-3881.
20. Melzner, I. & Möller, P. (2003) Silencing of the SOCS-1 gene by CpG methylation? Blood, 102, 1554-1555.
21. Nagai, H., Naka, T., Terada, Y., Komazaki, T., Yabe, A., Jin, E., Kawanami, O., Kishimoto, T., Konishi, N., Nakamura, M., Kobayashi, Y. & Emi, M. (2003) Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas. Journal of Human Genetics, 48, 65-69.
22. Ng, M.H., Lau, K.M., Wong, W.S., To, K.W., Cheng, S.H., Tsang, K.S., Chan, N.P., Kho, B.C., Lo, K.W., Tong, J.H., Lam, C.W. & Chan, J.C. (2003) Alterations of RAS signalling in Chinese multiple myeloma patients: absent BRAF and rare RAS mutations, but frequent inactivation of RASSF1A by transcriptional silencing or expression of a non-functional variant transcript. British Journal of Haematology, 123, 637-645.
23. Oka, T., Ouchida, M., Koyama, M., Ogama, Y., Takada, S., Nakatani, Y., Tanaka, T., Yoshino, T., Hayashi, K., Ohara, N., Kondo, E., Takahashi, K., Tsuchiyama, J., Tanimoto, M., Shimizu, K. & Akagi, T. (2002) Gene silencing of the tyrosine phosphastase SHP1 by aberrant methylation in leukemias/lymphomas. Cancer Research, 62, 6390-6394.
24. Ortiz-Vega, S., Khokhlatchev, A., Nedwidek, M., Zhang, X.F., Dammann, R., Pfeifer, G.P. & Avruch, J. (2002) The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene, 21, 1381-1390.
25. Paulson, R.F., Vesely, S., Siminovitch, K.A. & Bernstein, A. (1996) Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1. Nature Genetics, 13, 309-315.
26. Pfeifer, G.P., Yoon, J.H., Liu, L., Tommasi, S., Wilczynski, S.P. & Dammann, R. (2002) Methylation of the RASSF1A gene in human cancers. Biological Chemistry, 383, 907-914.
27. Reilly, J.T. (2003) Tyrosine kinase receptors (RTKs) in normal and malignant haematopoiesis. Blood Reviews, 17, 241-248.
28. Rottapel, R., Ilangumaran, S., Neale, C., La Rose, J., Ho, J.M., Nguyen, M.H., Barber, D., Dubreuil, P. & de Sepulveda, P. (2002) The tumor suppressor activity of SOCS-1. Oncogene, 21, 4351-4362.
29. Singer, G., Oldt, R., Cohen, Y., Wang, B.C., Sidransky, D., Kurman, R.J. & Shih, I-M. (2003) Mutations in BRAF and KRAS characterise the development of low-grade ovarian serous carcinoma. Journal of the National Cancer Institute, 95, 484-486.
30. Vos, M.D., Ellis, CA., Bell, A., Birrer, M.J. & Clarke, G.J. (2000) RAS uses the novel tumor suppressor RASSF1A as an effector to mediate apoptosis. Journal of Biological Chemistry, 275, 35669-35672.
31. Watanabe, D., Ezoe, S., Fujimoto, M., Kimura, A., Saito, Y., Nagai, H., Tachibana, I., Matsumura, I., Tanaka, T., Kanegane, H., Miyawaki, T., Emi, M., Kanakura, Y., Kawase, I., Naka, T. & Kishimoto, T. (2004) Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. British Journal of Haematology, 126, 726-735.
32. Wong, I.H., Chan, J., Wong, J. & Tam, P.K. (2004) Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia. Clinical Cancer Research, 10, 994-1002.
33. Wu, C., Sun, M., Liu, L. & Zhou, W. (2003) The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene, 306, 1-12.
34. Xing, M., Cohen, Y., Mambo, E., Tallini, G., Udelsman, R., Ladenson, P.W. & Sidransky, D. (2004) Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutations in thryoid tumorigenesis. Cancer Research, 64, 1664-1668.
35. Yoshikawa, H., Matsubara, K., Qian, G-S., Jackson, P., Groopman, I.D., Manning, J.E., Harris, C.C. & Herman, J.G. (2001) SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nature Genetics, 28, 29-35.